KindlyMD (NASDAQ:NAKA) CEO Buys $30,422.04 in Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 4,852 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was acquired at an average price of $6.27 per share, for a total transaction of $30,422.04. Following the transaction, the chief executive officer owned 3,185,246 shares in the company, valued at $19,971,492.42. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

KindlyMD Price Performance

NASDAQ NAKA traded up $0.76 during trading on Friday, hitting $7.06. 451,586 shares of the company’s stock traded hands, compared to its average volume of 199,173. The stock has a fifty day moving average of $4.48 and a two-hundred day moving average of $7.24. KindlyMD, Inc. has a 12-month low of $3.33 and a 12-month high of $422.40. The firm has a market cap of $126.37 million, a P/E ratio of -0.20 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) EPS for the quarter. The company had revenue of $35.87 million during the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%. As a group, analysts expect that KindlyMD, Inc. will post -11.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. TD Cowen raised their price target on shares of KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Finally, Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $22.33.

Institutional Investors Weigh In On KindlyMD

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of KindlyMD in the 4th quarter worth approximately $151,000. J. Derek Lewis & Associates Inc. bought a new position in shares of KindlyMD during the fourth quarter valued at approximately $167,000. Truist Financial Corp purchased a new stake in KindlyMD in the fourth quarter worth $176,000. Waddell & Associates LLC purchased a new stake in KindlyMD in the fourth quarter worth $201,000. Finally, Invesco Ltd. bought a new stake in KindlyMD in the fourth quarter valued at $211,000.

More KindlyMD News

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.